Double-whammy cancer treatment

Israel’s Kahr Medical plans to begin human trials of its DSP-107 treatment on lung cancer patients. It will be tested both standalone and in combination with Roche’s Tecentriq (atezolizumab). DSP-107 finds and marks cancer cells, then alerts the immune system and blocks the cancer.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *